DNA vaccines as promising immuno-therapeutics against cancer: a new insight
Cancer is one of the leading causes of mortality around the world and most of our conventional treatments are not efficient enough to combat this deadly disease. Harnessing the power of the immune system to target cancer cells is one of the most appealing methods for cancer therapy. Nucleotide-based...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1498431/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543865883951104 |
|---|---|
| author | Alireza Shariati Arya Khezrpour Fatemeh Shariati Hamed Afkhami Hamed Afkhami Hamed Afkhami Aref Yarahmadi Sajad Alavimanesh Sajad Alavimanesh Sina Kamrani Mohammad Hossein Modarressi Pouria Khani |
| author_facet | Alireza Shariati Arya Khezrpour Fatemeh Shariati Hamed Afkhami Hamed Afkhami Hamed Afkhami Aref Yarahmadi Sajad Alavimanesh Sajad Alavimanesh Sina Kamrani Mohammad Hossein Modarressi Pouria Khani |
| author_sort | Alireza Shariati |
| collection | DOAJ |
| description | Cancer is one of the leading causes of mortality around the world and most of our conventional treatments are not efficient enough to combat this deadly disease. Harnessing the power of the immune system to target cancer cells is one of the most appealing methods for cancer therapy. Nucleotide-based cancer vaccines, especially deoxyribonucleic acid (DNA) cancer vaccines are viable novel cancer treatments that have recently garnered significant attention. DNA cancer vaccines are made of plasmid molecules that encode tumor-associated or tumor-specific antigens (TAAs or TSAs), and possibly some other immunomodulatory adjuvants such as pro-inflammatory interleukins. Following the internalization of plasmids into cells, their genes are expressed and the tumor antigens are loaded on major histocompatibility molecules to be presented to T-cells. After the T-cells have been activated, they will look for tumor antigens and destroy the tumor cells upon encountering them. As with any other treatment, there are pros and cons associated with using these vaccines. They are relatively safe, usually well-tolerated, stable, easily mass-produced, cost-effective, and easily stored and transported. They can induce a systemic immune response effective on both the primary tumor and metastases. The main disadvantage of DNA vaccines is their poor immunogenicity. Several approaches including structural modification, combination therapy with conventional and novel cancer treatments (such as chemotherapy, radiotherapy, and immune checkpoint blockade (ICB)), and the incorporation of adjuvants into the plasmid structure have been studied to enhance the vaccine’s immunogenicity and improve the clinical outcome of cancer patients. In this review, we will discuss some of the most promising optimization strategies and examine some of the important trials regarding these vaccines. |
| format | Article |
| id | doaj-art-d4dffacc2db04a0bbf972181b936e762 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-d4dffacc2db04a0bbf972181b936e7622025-01-13T05:10:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14984311498431DNA vaccines as promising immuno-therapeutics against cancer: a new insightAlireza Shariati0Arya Khezrpour1Fatemeh Shariati2Hamed Afkhami3Hamed Afkhami4Hamed Afkhami5Aref Yarahmadi6Sajad Alavimanesh7Sajad Alavimanesh8Sina Kamrani9Mohammad Hossein Modarressi10Pouria Khani11School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, IranSchool of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, IranDepartment of Genetics, North Tehran Branch, Islamic Azad University, Tehran, IranCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, IranNervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, IranDepartment of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, IranDepartment of Biology, Khorramabad Branch, Islamic Azad University, Khorramabad, IranStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, IranCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranDepartment of Orthopedic, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran0Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran0Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, IranCancer is one of the leading causes of mortality around the world and most of our conventional treatments are not efficient enough to combat this deadly disease. Harnessing the power of the immune system to target cancer cells is one of the most appealing methods for cancer therapy. Nucleotide-based cancer vaccines, especially deoxyribonucleic acid (DNA) cancer vaccines are viable novel cancer treatments that have recently garnered significant attention. DNA cancer vaccines are made of plasmid molecules that encode tumor-associated or tumor-specific antigens (TAAs or TSAs), and possibly some other immunomodulatory adjuvants such as pro-inflammatory interleukins. Following the internalization of plasmids into cells, their genes are expressed and the tumor antigens are loaded on major histocompatibility molecules to be presented to T-cells. After the T-cells have been activated, they will look for tumor antigens and destroy the tumor cells upon encountering them. As with any other treatment, there are pros and cons associated with using these vaccines. They are relatively safe, usually well-tolerated, stable, easily mass-produced, cost-effective, and easily stored and transported. They can induce a systemic immune response effective on both the primary tumor and metastases. The main disadvantage of DNA vaccines is their poor immunogenicity. Several approaches including structural modification, combination therapy with conventional and novel cancer treatments (such as chemotherapy, radiotherapy, and immune checkpoint blockade (ICB)), and the incorporation of adjuvants into the plasmid structure have been studied to enhance the vaccine’s immunogenicity and improve the clinical outcome of cancer patients. In this review, we will discuss some of the most promising optimization strategies and examine some of the important trials regarding these vaccines.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1498431/fullDNA vaccinescancerimmunotherapyimmune responsevaccines |
| spellingShingle | Alireza Shariati Arya Khezrpour Fatemeh Shariati Hamed Afkhami Hamed Afkhami Hamed Afkhami Aref Yarahmadi Sajad Alavimanesh Sajad Alavimanesh Sina Kamrani Mohammad Hossein Modarressi Pouria Khani DNA vaccines as promising immuno-therapeutics against cancer: a new insight Frontiers in Immunology DNA vaccines cancer immunotherapy immune response vaccines |
| title | DNA vaccines as promising immuno-therapeutics against cancer: a new insight |
| title_full | DNA vaccines as promising immuno-therapeutics against cancer: a new insight |
| title_fullStr | DNA vaccines as promising immuno-therapeutics against cancer: a new insight |
| title_full_unstemmed | DNA vaccines as promising immuno-therapeutics against cancer: a new insight |
| title_short | DNA vaccines as promising immuno-therapeutics against cancer: a new insight |
| title_sort | dna vaccines as promising immuno therapeutics against cancer a new insight |
| topic | DNA vaccines cancer immunotherapy immune response vaccines |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1498431/full |
| work_keys_str_mv | AT alirezashariati dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT aryakhezrpour dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT fatemehshariati dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT hamedafkhami dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT hamedafkhami dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT hamedafkhami dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT arefyarahmadi dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT sajadalavimanesh dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT sajadalavimanesh dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT sinakamrani dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT mohammadhosseinmodarressi dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight AT pouriakhani dnavaccinesaspromisingimmunotherapeuticsagainstcanceranewinsight |